Anti-TALEN Antibodies and Uses Thereof

Anti-TALEN antibodies with specific sequences are developed to address the challenges of persistent nuclease activity and immunogenicity in genome editing tools, enabling safe and effective evaluation of TALEN and FokI proteins in gene editing therapies.

JP7580406B2Active Publication Date: 2024-11-11ALLOGENE THERAPEUTICS INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2021573273
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-06-13
Filing Date
2020-06-12
Publication Date
2024-11-11
Estimated Expiration
2040-06-12

AI Technical Summary

Technical Problem

Current genome editing tools like TALENs, ZFNs, and RFNs face challenges with persistent nuclease activity, off-target effects, and immunogenicity risks, necessitating the development of antibodies that can specifically bind to TALEN and FokI proteins for safety and efficacy assessment in gene editing therapies.

Method used

Development of anti-TALEN antibodies with specific variable heavy and light chain sequences, capable of binding to TALEN and FokI proteins, which can be used for detection and evaluation of gene editing processes, and potentially conjugated with detectable labels for quantitative analysis.

Benefits of technology

The anti-TALEN antibodies provide a means to assess the presence and activity of TALEN and FokI proteins, aiding in the safety and efficacy evaluation of genome editing therapies by ensuring precise and targeted binding, thereby reducing off-target effects and immunogenicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007580406000008
    Figure 0007580406000008
  • Figure 0007580406000001
    Figure 0007580406000001
  • Figure 0007580406000002
    Figure 0007580406000002
Patent Text Reader

Abstract

The present disclosure provides, inter alia, antibodies and methods of use thereof for detecting TALEN and / or FokI nucleases in a sample.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] cross reference This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 861,214, filed June 13, 2019, the contents of which are incorporated herein by reference in their entirety.

[0002] Sequence Listing This application contains a Sequence Listing that has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. This ASCII copy, created on June 12, 2020, is named AT-021_02_SL_ST25.txt and is 26,590 bytes in size.

[0003] The present disclosure relates to antigen binding molecules, including but not limited to antibodies that specifically bind to gene editing proteins (e.g., TALEN proteins that contain the catalytic domain FokI, also known as Fok-1 or Fok1), and polynucleotides encoding same, and methods of use. [Background technology]

[0004] Genome editing tools such as TAL effector nucleases (TALENs), zinc finger nucleases (ZFNs), and RNA-guided FokI nucleases (RFNs) are powerful tools that allow precise correction, insertion, or deletion of genes. TALENs, ZFNs, and RFNs can bind and cleave target sites in the genome. The resulting cleaved DNA is repaired via the endogenous cellular DNA repair mechanism of non-homologous end joining (NHEJ) or, when a repair template is provided, via homology-directed repair (HDR). TALENs use a TAL effector DNA binding domain fused to a DNA cleavage domain (e.g., FokI). ZFNs contain a restriction enzyme cleavage or catalytic domain, such as FokI, linked to an engineered Cys2His2 zinc finger, which is a DNA-binding polypeptide. RFNs contain a FokI nuclease fused to a catalytically inactive form of Cas9. For efficient genome editing in mammals (e.g., humans, dogs, cattle, non-human primates, etc.), TALENs, ZFNs, and RFNs are expected to be expressed at high levels. Due to persistent nuclease activity and off-target effects, as well as the risk of potential immunogenicity, there is a need in the art for antibodies that recognize genome editing tools that can bind to nuclease proteins (e.g., anti-TALENs and / or anti-FokI antibodies) to evaluate the safety and efficacy of various gene editing therapies. Summary of the Invention

[0005] The present disclosure provides antibodies for detecting FokI catalytic domain and full-length TALEN protein in samples.As described herein, including in the following examples, the present disclosure provides anti-TALEN antibodies that specifically bind to TALEN and FokI protein.In some embodiments, the anti-TALEN antibodies of the present disclosure can be used to evaluate gene editing therapy and process.

[0006] In one aspect, the disclosure provides an anti-TALEN antibody comprising a variable heavy chain amino acid sequence at least 85% identical to SEQ ID NO:3 and a variable light chain amino acid sequence at least 85% identical to SEQ ID NO:7. In one embodiment, the anti-TALEN antibody is humanized. In various embodiments, the antibody is selected from the group consisting of an antibody, a scFv, a Fab, a Fab', a Fv, a F(ab')2, a dAb, a human antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a polyclonal antibody, a recombinant antibody, an IgE antibody, an IgD antibody, an IgM antibody, an IgG1 antibody, an IgG1 antibody having at least one mutation in the hinge region, an IgG2 antibody, an IgG2 antibody having at least one mutation in the hinge region, an IgG3 antibody, an IgG3 antibody having at least one mutation in the hinge region, an IgG4 antibody, an IgG4 antibody having at least one mutation in the hinge region, an antibody comprising at least one non-naturally occurring amino acid, and any combination thereof.

[0007] In certain embodiments, the antibody comprises a variable heavy chain (HC) selected from the group consisting of SEQ ID NOs: 3-6, and in further embodiments, the anti-TALEN antibody comprises a heavy chain CDR1 selected from the group consisting of SEQ ID NOs: 12-14, and / or a heavy chain CDR2 selected from the group consisting of SEQ ID NOs: 15-20, and / or a heavy chain CDR3 comprising SEQ ID NO: 21. In certain embodiments, the anti-TALEN antibody comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3, each CDR comprising an amino acid sequence as shown in Table 1c. Anti-TALEN antibodies comprising a VH amino acid sequence that is at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the VH of an antigen binding molecule provided herein are also provided.

[0008] In other embodiments, the anti-TALEN antibody comprises a light chain variable region (VL) sequence selected from the group consisting of SEQ ID NO: 7-11. In certain embodiments, the anti-TALEN antibody comprises a light chain CDR1 comprising SEQ ID NO: 22, and / or a light chain CDR2 selected from the group consisting of SEQ ID NO: 23-25, and / or a light chain CDR3 selected from the group consisting of SEQ ID NO: 26-28. Anti-TALEN antibodies are further provided, wherein the light chain comprises a light chain CDR1, a light chain CDR2 and a light chain CDR3, each CDR comprising an amino acid sequence as set forth in Table 1d. Anti-TALEN antibodies are also provided that comprise a VL amino acid sequence that is at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the VL of the antigen binding molecule provided herein.

[0009] In another embodiment, provided herein is an anti-TALEN antibody comprising: (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 15; (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21; (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22; (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 23; and (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 26, and in a further embodiment, the anti-TALEN antibody comprises: (a) a VH comprising the amino acid sequence of SEQ ID NO: 3; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 7.

[0010] In another embodiment, provided herein is an anti-TALEN antibody comprising: (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 16; (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21; (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22; (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 24; and (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 27, and in a further embodiment, the anti-TALEN antibody comprises: (a) a VH comprising the amino acid sequence of SEQ ID NO: 3; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 8.

[0011] In a further embodiment, provided herein is an anti-TALEN antibody comprising: (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 13; (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 16; (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21; (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22; (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 25; and (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 26, in a further embodiment, the anti-TALEN antibody comprises: (a) a VH comprising the amino acid sequence of SEQ ID NO: 4; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 9.

[0012] In still further embodiments, provided herein is an anti-TALEN antibody comprising: (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 15; (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21; (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22; (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 24; and (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 28, and in further embodiments, the anti-TALEN antibody comprises: (a) a VH comprising the amino acid sequence of SEQ ID NO: 5; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 10.

[0013] Also provided is an anti-TALEN antibody comprising: (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 17; (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21; (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22; (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 24; and (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 27, and in a further embodiment, an anti-TALEN antibody of claim 23 comprising: (a) a VH comprising the amino acid sequence of SEQ ID NO: 6; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 11.

[0014] In various embodiments, the anti-TALEN antibody further comprises a detectable label, and in some embodiments, the detectable label is selected from the group consisting of a fluorescent label, a photochromic compound, a proteinaceous fluorescent label, a magnetic label, a radiolabel, and a hapten.When the detectable label is a fluorescent label, the fluorescent label may be selected from the group consisting of Atto dyes, Alexafluor dyes, quantum dots, hydroxycoumarins, aminocoumarins, methoxycoumarins, Cascade Blue, Pacific Blue, Pacific Orange, Lucifer Yellow, NBD, R-phycoerythrin (PE), PE-Cy5 conjugates, PE-Cy7 conjugates, Red 613, PerCP, TruRed, FluorX, fluorescein, BODIPY-FL, Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy7, TRITC, X-rhodamine, Lissamine Rhocamine B, Texas Red, allophycocyanin (APC), APC-Cy7 conjugates, Indo-1, Fluo-3, Fluo-4, DCFH, DHR, SNARF, GFP (Y66H mutant), GFP ( Y66F mutation), EBFP, EBFP2, Azurite, GFPuv, T-Sapphire, Cerulean, mCFP, mTurquoise2, ECFP, CyPet, GFP (Y66W mutation), mKeima-Red, TagCFP, AmCyan1, mTFP1, GFP (S65A mutation), Greenish cyan, wild-type GFP, GFP (S65C mutation), TurboGFP, TagGFP, GFP (S65L mutation), Emerald The antibody may be selected from the group consisting of Lardo, GFP (S65T mutation), EGFP, Thistle Green, ZsGreen1, TagYFP, EYFP, Topaz, Venus, mCitrine, YPet, TurboYFP, ZsYellow1, Kusabira Orange, mOrange, Allophycocyanin (APC), mKO, TurboRFP, tdTomato, TagRFP, DsRed monomer, DsRed2 ("RFP"), mStrawberry, TurboFP602, AsRed2, mRFP1, J-Red, R-phycoerythrin (RPE), B-phycoeryhring (BPE), mCherry, HcRed1, Katusha, P3, Peridinin Chlorophyll (PerCP), mKate (TagFP635), TurboFP635, mPlum, and mRaspberry. In certain embodiments, the fluorescent label is R-phycoerythrin (PE) or allophycocyanin (APC).

[0015] The anti-TALEN antibodies provided herein and an acceptable carrier or vector. H A vehicle, e.g., a pharma- ceutically acceptable carrier or vehicle. H Compositions comprising kuru are also provided.

[0016] Also provided is a polynucleotide encoding the heavy chain of the anti-TALEN antibody disclosed herein. Also provided is a polynucleotide encoding the light chain of the anti-TALEN antibody disclosed herein. Also provided is a vector comprising one or both of the heavy and light chain encoding polynucleotides. Additionally, a cell comprising one or both of the vectors is provided, and the cell may comprise a cell selected from the group consisting of CHO cells, Sp2 / 0 cells, rabbit cells and E. coli cells. Also provided is a method of producing the anti-TALEN antibody disclosed herein, comprising incubating a cell comprising one or both of the vectors described above under suitable conditions.

[0017] In yet another embodiment, a method for determining the presence or absence of TALEN protein in a sample is provided, in one embodiment, the method comprises contacting the sample with an anti-TALEN antibody conjugated with detectable label, and determining the presence or absence of TALEN protein in the sample, in some embodiments, the anti-TALEN antibody comprises the antibody provided herein or its humanized form.In addition, the sample can be tissue sample, blood sample, formalin-fixed sample, ex vivo grown tissue or cell culture medium.

[0018] Various aspects of the present disclosure are described in detail in the following sections. The use of sections is not intended to limit the present disclosure. Each section can be applied to any aspect of the present disclosure. In this application, the use of "or" means "and / or" unless otherwise stated. All references cited herein are incorporated by reference in their entirety. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0019] The drawings provided in this disclosure are for illustration purposes only and not for limitation. [Brief description of the drawings]

[0020] [Figure 1] FIG. 1 shows a Western blot analysis of hybridoma supernatants of fusion number 2299 (numbers 13-16 shown in the figure) and number 2296 (numbers 3, 6, 7, 8, and 11 shown in the figure).

[0021] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art (e.g., in the art of genetic engineering, cell culture, molecular genetics, nucleic acid chemistry, and biochemistry).

[0022] In order that this disclosure may be more readily understood, certain terms are first defined below. Additional definitions for the following terms, as well as other terms, are set forth throughout this disclosure.

[0023] Affinity: As known in the art, "affinity" refers to a measure of the tightness with which a particular ligand binds to its partner. Affinity can be measured in different ways. In some embodiments, affinity is measured by a quantitative assay. In some embodiments, the binding partner concentration and / or the ligand concentration can be varied. In some such embodiments, affinity can be compared to a reference under comparable conditions (e.g., concentration).

[0024] Amino acid: in its broadest sense, refers to any compound and / or substance that can be incorporated into a polypeptide chain, for example, through the formation of one or more peptide bonds. In some embodiments, an amino acid has the general structure H2N-C(H)(R)-COOH. In some embodiments, an amino acid is a naturally occurring amino acid. In some embodiments, an amino acid is a synthetic amino acid, in some embodiments, an amino acid is a D-amino acid, and in some embodiments, an amino acid is an L-amino acid. The term "standard amino acid" refers to any of the 20 standard L-amino acids commonly found in naturally occurring peptides. The term "non-standard amino acid" refers to any amino acid other than the standard amino acids, whether synthetically prepared or obtained from a natural source. In some embodiments, amino acids, including the carboxy-terminal amino acid and / or the amino-terminal amino acid in a polypeptide, may contain structural modifications compared to the general structure above. For example, in some embodiments, an amino acid may be modified by methylation, amidation, acetylation, and / or substitution compared to the general structure. As is clear from the context, in some embodiments, the term "amino acid" is used to refer to a free amino acid, and in some embodiments, to an amino acid residue of a polypeptide.

[0025] Antibody: As used herein, the term "antibody" refers to a type of antigen-binding protein that includes a polypeptide that contains sufficient classical immunoglobulin sequence elements to confer specific binding to a particular target antigen. As is known in the art, naturally occurring intact antibodies are approximately 150 kD tetrameric agents that contain two identical heavy chain polypeptides (about 50 kD each) and two identical light chain polypeptides (about 25 kD each) that bind to what is commonly referred to as a "Y-shaped" structure. Each heavy chain contains at least four domains (each about 110 amino acids long), an amino-terminal variable (VH) domain (located at the tip of the Y structure), followed by three constant domains: CH1, CH2, and a carboxy-terminal CH3 (located at the base of the stem of the Y). A short region commonly referred to as a "switch" connects the heavy chain variable and constant regions. A "hinge" connects the CH2 and CH3 domains to the rest of the antibody. Two disulfide bonds in this hinge region link the two heavy chain polypeptides together in an intact antibody. Each light chain contains two domains, an amino-terminal variable (VL) domain followed by a carboxy-terminal constant (CL) domain, which are separated from each other by another "switch". An intact antibody tetramer contains two heavy-light chain dimers, in which the heavy and light chains are linked together by one disulfide bond and two other disulfide bonds link the heavy chain hinge regions together, thus linking the dimers together to form a tetramer. Naturally produced antibodies are also glycosylated, typically on the CH2 domain. Each domain in a natural antibody has a structure characterized by an "immunoglobulin fold" formed from two beta sheets (e.g., three, four, or five stranded sheets) packed together in a compressed antiparallel beta barrel. Each variable domain contains three hypervariable loops known as "complement determining regions" (CDR1, CDR2, and CDR3), and four somewhat invariant "framework" regions (FR1, FR2, FR3, and FR4).When a natural antibody folds, the FR regions form beta sheets that provide a structural framework for the domain, and the CDR loop regions from both the heavy and light chains are brought together in three-dimensional space to generate a single hypervariable antigen-binding site located at the tip of a Y structure. The Fc region of a naturally occurring antibody binds to elements of the complement system and also binds to receptors on effector cells, including effector cells that mediate cytotoxicity, for example. In some embodiments, the antibody is polyclonal, and in some embodiments, the antibody is monoclonal.

[0026] Bonded: As used herein, the term "bonded" is understood to refer to a typically non-covalent association between or among two or more entities. A "direct" bond involves physical contact between the entities or moieties, whereas an "indirect" bond involves a physical interaction through physical contact with one or more intermediate entities.

[0027] Chromosome: As used herein, the term "chromosome" refers to a linear molecule of DNA with associated proteins in the nucleus of a eukaryotic cell that carries genes and functions in the transmission of genetic information.

[0028] Corresponding: As used herein, refers to the position / identity of an amino acid residue in a subject polypeptide. Those skilled in the art will understand that for simplicity, residues in a polypeptide are often designated using a standard numbering system based on the reference related polypeptide, such that an amino acid "corresponding" to a residue at position 190, for example, does not necessarily actually be the 190th amino acid in a particular amino acid chain, but rather corresponds to the residue found at 190 in the reference polypeptide, and those skilled in the art will readily understand how to identify a "corresponding" amino acid.

[0029] Detection moiety: As used herein, the term "detection moiety" refers to any element, molecule, functional group, compound, fragment, or moiety that is detectable. In some embodiments, a detection moiety is provided or utilized alone. In some embodiments, a detection moiety is provided and / or utilized in association with (e.g., bound to) another agent. Examples of detection moieties include various ligands, radionuclides (e.g., 3 H, 14 C. 18 F, 19 F, 32 P, 35 S, 135 I, 125 I, 123 I, 64 Cu, 187 Re, 111 In, 90 Y, 99m Tc, 177 Lu, 89 Zr, etc.), fluorescent dyes (e.g., fluorescein dyes, acridine dyes, SYBR dyes, rhodamine dyes, oxazine dyes, etc.), chemiluminescent agents (e.g., acridinam esters, stabilized dioxatanes, etc.), electrochemiluminescent agents (e.g., sulfotags, etc.), bioluminescent agents (e.g., luciferin, etc.), spectrally resolvable inorganic fluorescent semiconductor nanocrystals (i.e., quantum dots), metal nanoparticles (e.g., gold, silver, copper, platinum, etc.), nanoclusters, paramagnetic metal ions, enzymes (e.g., horseradish peroxidase, alkaline phosphatase, etc.), colorimetric labels (e.g., dyes, colloidal gold, etc.), biotin, digoxigenin, haptens, and proteins for which antisera or monoclonal antibodies are available.

[0030] Engineered: In general, the term "engineered" refers to aspects that have been manipulated by the hand of man. For example, a polynucleotide is considered to be "engineered" when two or more sequences that are not naturally linked together in that order are manipulated by the hand of man to be directly linked to each other in an engineered polynucleotide. For example, in some embodiments of the present disclosure, an engineered polynucleotide may include a regulatory sequence found in nature that is operably linked to a first coding sequence but not to a second coding sequence, and that is linked by the hand of man to be operably linked to a second coding sequence. Equivalently, a cell or organism is considered to be "engineered" when it has been engineered such that its genetic information is altered (e.g., new genetic material not presently present is introduced, e.g., by transformation, mating, somatic cell hybridization, transfection, transduction, or other mechanisms, or, e.g., by substitution or deletion mutations, or by mating protocols). As is common practice and will be understood by those of skill in the art, the progeny of an engineered polynucleotide or cell is typically still referred to as "engineered" even if the actual manipulation was performed on the previous entity.

[0031] Expression: As used herein, "expression" of a nucleic acid sequence refers to one or more of the following events: (1) production of an RNA template from a DNA sequence (e.g., by transcription), (2) processing of the RNA transcript (e.g., by splicing, editing, 5' capping, and / or 3' end formation), (3) translation of the RNA into a polypeptide or protein, and / or (4) post-translational modification of the polypeptide or protein.

[0032] FokI: As used herein, the term "FokI" (alternatively referred to as Fok1 or Fok-1) refers to a bacterial type IIS restriction endonuclease found naturally in Flavobacterium oceanokoites. Naturally occurring FokI contains an N-terminal DNA binding domain and a C-terminal non-specific DNA cleavage domain. The FokI DNA cleavage domain may function independently of the DNA binding domain. As used herein, FokI refers to a protein or a nucleic acid encoding a protein that contains the DNA cleavage domain (i.e., nuclease domain) of FokI. FokI can refer to the entire FokI protein (SEQ ID NO:2), or only the catalytic nuclease domain (SEQ ID NO:1). The term "FokI" refers to all fragments and variants of FokI, including mutants, derivatives, analogs, truncations, fusion constructs, and multimers of FokI, including FokI dimers. In some embodiments, FokI is produced recombinantly. In some embodiments, the FokI polypeptide is conjugated or tagged with additional moieties, such as binding moieties and / or detection moieties. As is clear from the context, in some embodiments, the term "FokI" is used to refer to the FokI polypeptide or a fragment or variant thereof, and in some embodiments, FokI is used to refer to the nucleic acid encoding the FokI polypeptide and fragments and variants thereof.

[0033] Fragment: A "fragment" of a biological molecule as described herein comprises a distinct portion of the whole, but has a structure that lacks one or more portions found in the whole (e.g., a polypeptide lacking one or more amino acids). In some embodiments, a fragment consists of such a distinct portion. In some embodiments, a fragment consists of or includes a characteristic structural element or portion found in the whole (e.g., a polypeptide domain). In some embodiments, a biological molecule is a polymer (e.g., a nucleic acid polymer or a polypeptide). In some embodiments, a polymer fragment comprises or consists of at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500 or more monomeric units (e.g., residues) found throughout the polymer. In some embodiments, a polymer fragment comprises or consists of at least about 5%, 10%, 15%, 20%, 25%, 30%, 25%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more of the monomeric units (e.g., residues) found in the entire polymer. In some embodiments, an entire biological molecule can be referred to as the "parent" of the whole.

[0034] Fusion: A "fusion molecule" is a molecule in which two or more subunit molecules are preferably covalently linked. The subunit molecules may be molecules of the same chemical type or molecules of different chemical types. Examples of fusions of molecules of the same chemical type include, but are not limited to, fusion proteins (e.g., fusions between a zinc finger protein or a TALEN DNA binding domain to a FokI cleavage domain) and fusion nucleic acids (e.g., nucleic acids encoding the above fusion proteins). Examples of fusions of molecules of different chemical types include, but are not limited to, fusions of nucleic acids and polypeptides (e.g., fusions between an RNA molecule and a FokI cleavage domain).

[0035] Gene: As used herein, the term "gene" refers to a DNA sequence that codes for a product (e.g., an RNA product and / or a polypeptide product). In some embodiments, a gene includes a coding sequence (i.e., a sequence that codes for a particular product), and in some embodiments, a gene includes a non-coding sequence. In some particular embodiments, a gene may include both coding (e.g., exon) and non-coding (e.g., intron) sequences. In some embodiments, a gene may include one or more regulatory elements that, for example, may control or affect one or more aspects of gene expression (e.g., cell type specific expression, inducible expression, etc.).

[0036] Gene or cell therapy: As used herein, the term "gene or cell therapy" refers to the insertion or deletion of a specific genomic DNA sequence to treat or prevent a disorder or condition for which such therapy is sought. In some embodiments, the insertion or deletion of the genomic DNA sequence occurs in a specific cell (i.e., the target cell). The target cell may be of mammalian origin and / or may be a cell in a mammalian subject. Mammals include, but are not limited to, humans, dogs, cats, cows, sheep, pigs, llamas, non-human primates, and the like. In some embodiments, heterologous DNA is transferred to the target cell. Heterologous DNA may be introduced into a selected target cell such that the heterologous DNA is expressed and a therapeutic product encoded thereby is produced. Additionally or alternatively, the heterologous DNA may code for a product, such as a peptide or RNA, that in some way mediates expression of the DNA encoding the therapeutic product or that in some way directly or indirectly mediates expression of the therapeutic product. Gene therapy or cell therapy may be used to deliver a nucleic acid encoding a gene product that replaces a defective gene or adds to the gene product produced by the mammal or cell into which it is introduced. Heterologous DNA encoding a therapeutic product can be modified prior to introduction into the cells of an affected subject to enhance or otherwise alter the product or its expression. Gene therapy or cell therapy can also involve delivery of inhibitors, suppressors, or other regulators of gene expression. Gene therapy can include in vivo or ex vivo techniques. In some embodiments, gene therapy or cell therapy includes administering a nucleic acid encoding a TAL effector nuclease (TALEN), zinc finger nuclease (ZFN), or RNA-guided FokI nuclease (RFN). In some embodiments, viral and non-viral based gene transfer methods can be used to introduce nucleic acids encoding TALENs, ZFNs, or RFNs into mammalian cells or target tissues. Such methods can be used to administer nucleic acids encoding TALENs, ZFNs, or RFNs to cells in vitro.Non-viral vector delivery systems include DNA plasmids, naked nucleic acid, and delivery vectors such as poloxamers or liposomes. H The viral vector delivery system includes DNA and RNA viruses that have either episomal or integrated genomes after delivery to cells. For a summary of gene therapy approaches, see, for example, Anderson, Science 256:808-813 (1992); Miller, Nature 357:455-460 (1992); Feuerbach et al., Kidney International 49:1791-1794 (1996); Urnov et al., Nature Reviews Genetics 11, 636-646 (2010); and Collins et al., Proceedings Biologicial Sciences / The Royal Society, 282 (1821): pii 20143003 (2015).

[0037] Genome: As used herein, the term "genome" refers to the total genetic information carried by an individual organism or cell, represented by the complete DNA sequence of its chromosomes.

[0038] High affinity binding: As used herein, the term "high affinity binding" refers to a high degree of tightness with which a particular ligand binds to its partner. Affinity can be measured by any available method, including those known in the art. In some embodiments, K d is about 500 pM or less (e.g., about 400 pM, about 300 pM, about 200 pM, about 100 pM, about 90 pM, about 80 pM, about 70 pM, about 60 pM, about 50 pM, about 40 pM, about 30 pM, about 20 pM, about 10 pM, about 5 pM, about 4 pM, about 3 pM, about 2 pM, etc.) in a binding assay. In some embodiments, the affinity is stronger (e.g., K dIn some embodiments, the binding is considered to be of high affinity if the K for the selected reference polypeptide is lower. d K for the polypeptide of interest d Binding is considered to be of high affinity when the ratio of K for a polypeptide of interest is 1:1 or less (e.g., 0.9:1, 0.8:1, 0.7:1, 0.6:1, 0.5:1, 0.4:1, 0.3:1, 0.2:1, 0.1:1, 0.05:1, 0.01:1, or less). d is the K for the selected reference polypeptide d Binding is considered to be of high affinity if the affinity is about 100% or less (e.g., about 99%, about 98%, about 97%, about 96%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, about 50%, about 45%, about 40%, about 35%, about 30%, about 25%, about 20%, about 15%, about 10%, about 5%, about 4%, about 3%, about 2%, about 1% or less) of the total affinity.

[0039] Homology: As used herein, the term "homology" refers to the overall relatedness between polymer molecules, e.g., between nucleic acid molecules (e.g., DNA molecules and / or RNA molecules) and / or between polypeptide molecules. In some embodiments, polymer molecules are considered to be "homologous" to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical. In some embodiments, polymer molecules are considered to be "homologous" to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% similar.

[0040] In vitro: As used herein, the term "in vitro" refers to events that take place not within a multicellular organism but in an artificial environment, e.g., in a test tube or reaction vessel, in cell culture, etc.

[0041] In vivo: As used herein, refers to events that occur within multicellular organisms, such as humans and non-human animals. In the context of cell-based systems, the term may be used to refer to events that occur within living cells (e.g., as opposed to in vitro systems).

[0042] Isolated: As used herein, refers to (1) a substance and / or entity that is separated from at least some of the components with which it is associated when originally produced (either in nature and / or in an experimental environment) and / or (2) a substance and / or entity that is designed, produced, prepared, and / or manufactured by the hand of man. Isolated substances and / or entities may be separated from about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or greater than about 99% of other components with which they are originally associated. In some embodiments, an isolated agent is about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more pure. As used herein, a substance is pure if it is substantially free of other components. In some embodiments, as understood by those skilled in the art, a substance can still be considered to be "isolated" or even "pure" after being combined with certain other components, such as, for example, one or more carriers or excipients (e.g., buffers, solvents, water, etc.), and in such embodiments, the percentage of isolation or purity of a substance is calculated without including such carriers or excipients. By way of example, in some embodiments, a biological polymer, such as a naturally occurring polypeptide or polynucleotide, is considered to be "isolated" when: a) by virtue of its origin or source of derivation, it is not associated with some or all of the components that naturally accompany it in its natural state; b) it is substantially free of other polypeptides or nucleic acids of the same species as the species in which it occurs in nature; or c) it is expressed by or is otherwise associated with components derived from a cell or other expression system other than the species in which it occurs in nature. Thus, for example, in some embodiments, a polypeptide that is chemically synthesized or synthesized in a cellular system different from that in which it naturally occurs is considered to be an "isolated" polypeptide.Alternatively, or in addition, in some embodiments, a polypeptide that has been subjected to one or more purification techniques is considered to be an "isolated" polypeptide so long as a) it has been separated from other components with which it is naturally associated, and / or b) it was associated when originally produced.

[0043] Linker: as used herein, is used to refer to that portion of a multi-element polypeptide that connects different elements together. For example, those skilled in the art will understand that a polypeptide whose structure includes two or more functional or organizational domains will often include a stretch of amino acids between such domains that connects them together. In some embodiments, a polypeptide that includes a linker element has an overall structure of the general form S1-L-S2, where S1 and S2, which may be the same or different, represent two domains that are connected together by a linker. In some embodiments, the linker is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more amino acids in length. In some embodiments, the linker is characterized in that it does not tend to adopt a rigid three-dimensional structure, but rather provides flexibility to the polypeptide. There are a variety of different linker elements known in the art (see, for example, Holliger, P., et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak, RJ, et al. (1994) Structure 2:1 121-1123) that can be used appropriately when engineering polypeptides (e.g., fusion polypeptides).

[0044] Nucleic Acid: As used herein, in its broadest sense, the term "nucleic acid" refers to any compound and / or substance that is or can be incorporated into an oligonucleotide chain. In some embodiments, a nucleic acid is a compound and / or substance that is or can be incorporated into an oligonucleotide chain via a phosphodiester bond. As is clear from the context, in some embodiments, a "nucleic acid" refers to an individual nucleic acid residue (e.g., nucleotide and / or nucleoside), and in some embodiments, a "nucleic acid" refers to an oligonucleotide chain that includes individual nucleic acid residues. In some embodiments, a "nucleic acid" is or includes RNA, and in some embodiments, a "nucleic acid" is or includes DNA. In some embodiments, a nucleic acid is, includes, or consists of one or more naturally occurring nucleic acid residues. In some embodiments, a nucleic acid is, includes, or consists of one or more nucleic acid analogs. In some embodiments, a nucleic acid has a nucleotide sequence that encodes a functional gene product, such as an RNA or a protein. In some embodiments, a nucleic acid includes one or more introns. In some embodiments, the nucleic acid is prepared by one or more of isolation from a natural source, enzymatic synthesis by polymerization based on a complementary template (in vivo or in vitro), replication in a recombinant cell or system, and chemical synthesis. In some embodiments, the nucleic acids are at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000 or more residues in length. In some embodiments, the nucleic acid is single stranded, in some embodiments, the nucleic acid is double stranded, in some embodiments, the nucleic acid has a nucleotide sequence that includes at least one element that encodes a polypeptide or is the complement of a sequence that encodes a polypeptide.In some embodiments, the nucleic acid has enzymatic activity.

[0045] Physiological conditions: as used herein has its art-understood meaning referring to the conditions in which a cell or organism lives and / or reproduces. In some embodiments, the term refers to the conditions of the external or internal environment that may occur naturally for an organism or cellular system. In some embodiments, physiological conditions are those conditions present inside the body of a human or non-human animal, particularly those conditions present at and / or within a surgical site. Physiological conditions typically include, for example, a temperature range of about 20 to about 40° C., atmospheric pressure of about 1, pH of about 6 to about 8, glucose concentration of about 1 to about 20 mM, oxygen concentration at atmospheric levels, and gravity as encountered on Earth. In some embodiments, conditions in the laboratory are manipulated and / or maintained at physiological conditions. In some embodiments, physiological conditions are encountered in an organism.

[0046] Polypeptide: As used herein, the term "polypeptide" generally has its art-recognized meaning of a polymer of at least three amino acids. Those of skill in the art will appreciate that the term "polypeptide" is intended to encompass not only polypeptides having the complete sequences listed herein, but also polypeptides that represent functional fragments of such complete polypeptides (i.e., fragments that retain at least one activity). Moreover, those of skill in the art will appreciate that protein sequences generally tolerate some substitutions without destroying activity. Thus, any polypeptide that retains activity and further typically includes at least one region of much higher, frequently greater than 90%, or 95%, 96%, 97%, 98%, or 99% identity in one or more highly conserved regions, and typically shares at least about 30-40%, and frequently greater than about 50%, 60%, 70%, or 80% overall sequence identity with another polypeptide of the same class, encompassing at least 3-4, and frequently up to 20 or more amino acids, is encompassed within the related term "polypeptide" as used herein. Polypeptides may contain L-amino acids, D-amino acids, or both, and may contain any of a variety of amino acid modifications or analogs known in the art. Useful modifications include, for example, terminal acetylation, amidation, methylation, and the like. In some embodiments, proteins may contain natural amino acids, unnatural amino acids, synthetic amino acids, and combinations thereof. The term "peptide" is generally used to refer to a polypeptide having a length of less than about 100 amino acids, less than about 50 amino acids, less than 20 amino acids, or less than 10 amino acids. In some embodiments, the protein is an antibody, an antibody fragment, a biologically active portion thereof, and / or a characteristic portion thereof.

[0047] Protein: As used herein, the term "protein" refers to one or more polypeptides that function as separate units. Where a single polypeptide is a separate functional unit and does not require permanent or temporary physical association with other polypeptides to form a separate functional unit, the terms "polypeptide" and "protein" can be used interchangeably. Where a separate functional unit includes more than one polypeptide that physically associates with each other, the term "protein" can be used to refer to multiple polypeptides that are physically associated and function together as separate units. In some embodiments, a protein can include moieties other than amino acids (e.g., glycoproteins, proteoglycans, etc.) and / or can be otherwise processed or modified. One of skill in the art will appreciate that in some embodiments, the term "protein" can refer to an entire polypeptide chain produced by a cell (e.g., with or without a signal sequence) and / or a form that is active within the cell (e.g., a truncated or complexed form). In some embodiments where a protein is comprised of multiple polypeptide chains, such chains may be covalently linked to each other, e.g., by one or more disulfide bonds, or may be linked by other means.

[0048] Reference: as used herein in a scientific context, describes a standard or control against which a comparison is made. For example, in some embodiments, a subject agent, animal, individual, population, sample, sequence or value is compared to a reference or control agent, animal, individual, population, sample, sequence or value. In some embodiments, the reference or control is tested and / or identified substantially simultaneously with the subject test or determination. In some embodiments, the reference or control is a historical reference or control, optionally embodied in a physical medium. Typically, as understood by those skilled in the art, a reference or control is determined or characterized under conditions or circumstances equivalent to those being evaluated. Those skilled in the art will understand when there is sufficient similarity to justify reliance and / or comparison to a particular potential reference or control.

[0049] Sample: As used herein, the term "sample" typically refers to a biological sample obtained or derived from a subject source, as described herein. In some embodiments, the subject source includes an organism, such as an animal or human. In some embodiments, the biological sample is or includes a biological tissue or liquid. In some embodiments, the biological sample may be or include bone marrow; blood; any type of blood cell (e.g., T cells); ascites; tissue or fine needle biopsy sample; cell-containing body fluid; free floating nucleic acid; sputum; saliva; urine; cerebrospinal fluid, ascites; pleural fluid; feces; lymphatic fluid; gynecological body fluid; skin swab; vaginal swab; oral swab; nasal swab; washings or lavages, such as ductal lavage or bronchoalveolar lavage; aspirates; scrapings; bone marrow specimens; tissue biopsy specimens; surgical specimens; feces, other body fluids, secretions, and / or excretions; and / or cells derived therefrom, and the like. In some embodiments, the biological sample is or includes cells obtained from an individual. In some embodiments, the obtained cells are or include cells from the individual from whom the sample was obtained. In some embodiments, the sample is a "primary sample" obtained directly from the subject's source by any suitable means. For example, in some embodiments, the primary biological sample is obtained by a method selected from the group consisting of biopsy (e.g., fine needle aspiration or tissue biopsy), surgery, collection of bodily fluids (e.g., blood, lymph, feces, etc.), and the like. In some embodiments, as is clear from the context, the term "sample" refers to a preparation obtained by processing the primary sample (e.g., by removing one or more components and / or adding one or more agents). For example, filtration using a semi-permeable membrane. Such a "processed sample" may include, for example, nucleic acids or proteins extracted from the sample or obtained by subjecting the primary sample to techniques such as amplification or reverse transcription of mRNA, isolation and / or purification of specific components.

[0050] Specific binding: as used herein, refers to the ability of a binding agent to distinguish between possible partners in the environment in which binding occurs. A binding agent that interacts with one particular target in the presence of other potential targets is said to "specifically bind" to the target with which it interacts. In some embodiments, specific binding is assessed by detecting or determining the degree of binding between the binding agent and its partner, in some embodiments, specific binding is assessed by detecting or determining the degree of dissociation of the binding agent-partner complex, in some embodiments, specific binding is assessed by detecting or determining the ability of a binding agent to compete for an alternative interaction between its partner and another entity. In some embodiments, specific binding is assessed by performing such detection or determination over a range of concentrations.

[0051] Subject: "Subject" refers to a mammal (e.g., a human, in some embodiments, a human including prenatal human forms). In some embodiments, the subject is afflicted with the relevant disease, disorder, or condition. In some embodiments, the subject is susceptible to the disease, disorder, or condition. In some embodiments, the subject exhibits one or more symptoms or characteristics of the disease, disorder, or condition. In some embodiments, the subject does not exhibit symptoms or characteristics of the disease, disorder, or condition. In some embodiments, the subject possesses one or more characteristics characteristic of susceptibility or risk for a disease, disorder, or condition. In some embodiments, the subject is a patient. In some embodiments, the subject is an individual to whom a diagnosis and / or treatment has been and / or will be administered.

[0052] Substantially: As used herein, the term "substantially" refers to a qualitative state that exhibits the extent or degree of the total or near total of a feature or characteristic of interest. Those skilled in the biological arts understand that biological and chemical phenomena rarely, if ever, proceed to completion and / or perfection, or achieve or avoid absolute results. Thus, the term "substantially" is used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.

[0053] Variant: As used herein, the term "variant" refers to an entity that exhibits significant structural identity with a reference entity, but is structurally different from the reference entity in the presence or level of one or more chemical moieties compared to the reference entity. In many embodiments, a variant is also functionally different from the reference entity. In general, whether a particular entity is properly considered to be a "variant" of a reference entity is based on the degree of structural identity with the reference entity. As will be understood by those skilled in the art, any biological or chemical reference entity has certain characteristic structural elements. A variant is, by definition, a distinct chemical entity that shares one or more such characteristic structural elements. To give some examples, small molecule variants share a core structural element and characteristic pendant moieties, but differ in other pendant moieties and / or the type of linkages present within the core (e.g., singlet vs. doublet, E vs. Z, etc.), polypeptides can have characteristic sequence elements comprising multiple amino acids that have designated positions relative to one another in linear or three-dimensional space and / or contribute to a particular biological function, and nucleic acids can have characteristic sequence elements comprising multiple nucleotide residues that have designated positions relative to one another in linear or three-dimensional space. For example, variant polypeptides can differ from reference polypeptides as a result of one or more differences in amino acid sequence and / or one or more differences in chemical moieties (e.g., carbohydrates, lipids, etc.) covalently attached to the polypeptide backbone. In some embodiments, the variant polypeptide exhibits an overall sequence identity with the reference polypeptide that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. Alternatively, or in addition, in some embodiments, the variant polypeptide does not share at least one characteristic sequence element with the reference polypeptide. In some embodiments, the reference polypeptide has one or more biological activities. In some embodiments, the variant polypeptide shares one or more of the biological activities of the reference polypeptide.In some embodiments, a variant polypeptide lacks one or more of the biological activities of a reference polypeptide. In some embodiments, a variant polypeptide exhibits a reduced level of one or more biological activities compared to a reference polypeptide. In many embodiments, a subject polypeptide is considered to be a "variant" of a parent or reference polypeptide when the subject polypeptide has an amino acid sequence identical to that of the parent, but has a small number of sequence changes at certain positions. Typically, less than 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% of the residues in the variant are substituted compared to the parent. In some embodiments, a variant has 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 substituted residues compared to the parent. Frequently, a variant has a very small number (e.g., less than 5, 4, 3, 2 or 1) of functional residues (i.e., residues involved in a particular biological activity) substituted. Moreover, compared to the parent, the variant typically has no more than 5, 4, 3, 2, or 1 additions or deletions, and frequently has no additions or deletions. Moreover, any additions or deletions are typically less than about 25, about 20, about 19, about 18, about 17, about 16, about 15, about 14, about 13, about 10, about 9, about 8, about 7, about 6, and generally less than about 5, about 4, about 3, or about 2 residues. In some embodiments, the parent or reference polypeptide is one found in nature. In some embodiments, the variant is engineered. In some embodiments, the variant is naturally occurring. As will be understood by those skilled in the art, multiple variants of a particular polypeptide of interest can be found in nature.

[0054] Vector: As used herein, refers to a nucleic acid molecule capable of transporting another nucleic acid to which it is linked. One type of vector is a "plasmid", which refers to a circular double-stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector (e.g., lentiviral vector or gammaretroviral vector), in which additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors with a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can integrate into the genome of a host cell when introduced into the host cell, thereby replicating along with the host genome. In addition, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors".

[0055] Standard techniques can be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). Enzymatic reactions and purification techniques can be performed according to manufacturer's specifications or as commonly accomplished in the art or as described herein. The techniques and procedures described above can generally be performed according to conventional methods well known in the art and as described in various general and more specific references cited and discussed throughout this specification. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual (2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989)), which is incorporated herein by reference for any purpose.

[0056] Zinc finger protein: As used herein, the term "zinc finger protein" refers to a polypeptide that contains a "zinc finger domain" through which it is capable of binding to nucleic acids (e.g., DNA). The term "zinc finger domain" refers to an individual "finger" that contains a ββα-fold stabilized by a zinc ion. Each zinc finger domain typically contains approximately 30 amino acids. Zinc finger domains are largely structurally independent and can retain their structure and function in different environments.

[0057] As used in this application, the terms "about" and "approximately" are used as equivalents. Any numbers used in this application, whether about / approximately or not, are meant to cover any normal variations understood by one of ordinary skill in the art.

[0058] Other features, objects, and advantages of the present disclosure will become apparent from the following detailed description. It should be understood, however, that the detailed description, while illustrating embodiments of the present disclosure, is provided for purposes of illustration and not limitation. Various changes and modifications within the scope of the present disclosure will become apparent to those skilled in the art from the detailed description. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0059] The present disclosure provides antibodies that bind to TALEN proteins and / or FokI catalytic DNA cleavage domains, and uses thereof.

[0060] As used herein, an antibody includes, but is not limited to, an antibody binding region that is an immunologically functional fragment. The term "immunologically functional fragment" (or "fragment") of an antibody is a type of antibody that includes a portion of an antibody (regardless of how the portion is obtained or synthesized) that lacks at least some of the amino acids present in the full-length chain but still has the ability to specifically bind to a target antigen (e.g., bind to FokI and / or TALEN protein). Such fragments are biologically active in that they can bind to a target antigen and compete with other antigen-binding molecules, including intact antibodies, for binding to a given epitope. In some embodiments, the fragments are neutralizing fragments. In some embodiments, the fragments can block or reduce the activity of the target antigen (e.g., blocking effect). In some embodiments, the fragments can antagonize the activity of the target antigen.

[0061] In certain embodiments, the anti-TALEN antibody of the present disclosure is the antibody identified herein as clone 2299.2G3.C6, 2299.5D4.C8, 2299.6B3.B8.B6, 2299.6G5.C7, or 2299.7F11.B4, each of which comprises the heavy and light chain amino acid, coding sequence, variable sequence, and CDR sequence provided herein and labeled. In some embodiments, clone 2299.2G3.C6, 2299.5D4.C8, 2299.6B3.B8.B6, 2299.6G5.C7, or 2299.7F11.B4 specifically binds to a molecule that comprises FokI catalytic domain.

[0062] Immunologically functional immunoglobulin fragments include, but are not limited to, scFv fragments, Fab fragments (Fab', F(ab')2, etc.), one or more complementarity determining regions ("CDRs"), diabodies (a heavy chain variable domain and a light chain variable domain on the same polypeptide linked via a short peptide linker that is too short to allow pairing between the two domains on the same chain), domain antibodies, bivalent antigen-binding domains (comprising two antigen-binding sites), multispecific antigen-binding domains, and single-chain antibodies. These fragments may be derived from any mammal, including, but not limited to, human, mouse, rat, camelid, or rabbit. As will be appreciated by those skilled in the art, antigen-binding molecules may include non-proteinaceous components.

[0063] Variable regions typically exhibit the same general structure of relatively conserved framework regions (FRs) bound by three hypervariable regions (CDRs). The CDRs of the two chains of each pair are typically aligned by the framework regions, which allows binding to a specific epitope. From the N-terminus to the C-terminus, both light chain variable regions and heavy chain variable regions typically comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. By convention, the CDR regions in the heavy chain are typically referred to as HC CDR1, CDR2, and CDR3. The CDR regions in the light chain are typically referred to as LC CDR1, CDR2, and CDR3.

[0064] In some embodiments, the anti-TALEN antibody comprises one or more complementary binding regions (CDRs) present in the full-length light or heavy chain of the antibody, and in some embodiments, comprises a single heavy and / or light chain or a portion thereof. These fragments may be produced by recombinant DNA technology or by enzymatic or chemical cleavage of the antigen-binding domain comprising the intact antibody.

[0065] In some embodiments, the antigen-binding domain is an antibody of which it is a fragment and which comprises one or more of its complementarity determining regions (CDRs). In some embodiments, the antigen-binding domain is a single chain variable fragment (scFv) comprising light chain CDRs CDR1, CDR2 and CDR3, and heavy chain CDRs CDR1, CDR2 and CDR3.

[0066] The assignment of amino acids to each of the framework, CDR, and variable domains is typically based on the Kabat numbering (see, e.g., Kabat et al. in Sequences of Proteins of Immunological Interest, 5th Ed., NIH Publication 91-3242, Bethesda Md. 1991), Chothia numbering (see, e.g., Chothia & Lesk, (1987), J Mol Biol 196:901-917; Al-Lazikani et al., (1997) J Mol Biol 273:927-948; Chothia et al., (1992) J Mol Biol 227:799-817; Tramontano et al., (1990) J Mol Biol 215(1):175-82; and U.S. Pat. No. 7,709,226), contact numbering, or the AbM scheme (Antibody Modeling program, Oxford Molecular.

[0067] Therefore, in some embodiments, the CDRs of the anti-TALEN antibody presented herein are numbered according to the Kabat numbering scheme.In other embodiments, the CDRs of the anti-TALEN antibody presented herein are numbered according to the Chothia numbering scheme.In other embodiments, the CDRs of the anti-TALEN antibody presented herein are numbered according to the contact numbering scheme.In other embodiments, the CDRs of the anti-TALEN antibody presented herein are numbered according to the AbM numbering scheme.

[0068] The humanized antibody of the anti-TALEN antibody described herein can be prepared by known techniques. In some embodiments, the humanized monoclonal antibody comprises the variable domain of the anti-TALEN antibody (or all or part of its antigen-binding site) and the constant domain from a human antibody. Alternatively, the humanized antibody fragment can comprise the antigen-binding site of a mouse or rabbit monoclonal antibody and the variable domain fragment (lacking the antigen-binding site) from a human antibody. Techniques for the production of engineered monoclonal antibodies include those described in Riechmann et al., (1988) Nature 332:323, Liu et al., (1987) Proc. Nat.Acad.Sci.USA 84:3439, Larrick et al., (1989) Bio / Technology 7:934, and Winter et al., (1993) TIPS 14:139. In some embodiments, the chimeric antibody is a CDR-grafted antibody. Techniques for humanizing antibodies are described in, e.g., U.S. Pat. Nos. 5,869,619, 5,225,539, 5,821,337, 5,859,205, 6,881,557, Padlan et al., (1995) FASEB J. 9:133-39, Tamura et al., (2000) J. Immunol. 164:1432-41; Zhang et al., (2005) Mol. Immunol. 42(12):1445-1451; Hwang et al., Methods. (2005) 36(1):35-42, Dall'Acqua et al., (2005) Methods 36(1):43-60, and Clark, (2000) Immunology Today 21(8):397-402.

[0069] Variants of anti-TALEN antibodies are also within the scope of the present disclosure, for example, variable light chains and / or variable heavy chains each having at least 70-80%, 80-85%, 85-90%, 90-95%, 95-97%, 97-99%, or more than 99% identity to the amino acid sequence of the antigen binding domain sequence described herein. In some embodiments, the anti-idiotypic antibody is at least about 75%, at least about 85%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to the heavy chain variable region sequence provided in Table 1a and / or the light chain variable sequence provided in Table 1b.

[0070] In some cases, such molecules comprise at least one heavy chain and one light chain, while in other cases, variant forms comprise two variable light chains and two variable heavy chains (or portions thereof).Those skilled in the art can use well-known techniques to determine suitable variants of anti-TALEN antibodies described herein.In certain embodiments, those skilled in the art can identify suitable regions of molecules that can be altered without destroying antigen binding activity by targeting regions that are not considered important for activity.

[0071] The anti-TALEN antibody of the present disclosure may also be a fully human monoclonal antibody. Fully human monoclonal antibodies can be generated by any of a number of techniques familiar to those skilled in the art. These methods include, but are not limited to, Epstein-Barr Virus (EBV) transformation of human peripheral blood cells (e.g., containing B lymphocytes), in vitro immunization of human B cells, fusion of spleen cells from immunized transgenic mice carrying inserted human immunoglobulin genes, isolation from a human immunoglobulin V-region phage library, or other techniques known in the art and based on the disclosure herein.

[0072] An anti-TALEN antibody that specifically binds to a TALEN protein and / or FokI catalytic domain is said to be "selective" when it binds to one target more strongly than it binds to a second target. An anti-TALEN antibody that specifically binds to a TALEN protein and / or FokI catalytic domain is said to "specifically bind" to its target antigen (e.g., TALEN protein and / or FokI catalytic domain) when the dissociation constant (Kd) is in the nanomolar range (e.g., about 1 nM). An antigen-binding domain specifically binds to an antigen with "high affinity" when the Kd is 1-5 nM and with "ultra-high affinity" when the Kd is 0.1-0.5 nM. In one embodiment, the antigen-binding domain has a Kd of about 1 nM. In one embodiment, the off-rate is <1×10 -5 In other embodiments, the antigen binding domain is at about 1×10 to a molecule comprising a TALEN protein and a FokI catalytic domain. -7 M~1×10 -12 In yet another embodiment, the antigen-binding domain binds with a Kd of about 1×10 -5 ~1×10 -12 It binds with a Kd of

[0073] As provided herein, the anti-TALEN antibodies of the present disclosure specifically bind to a TALEN protein and / or a FokI nuclease domain (e.g., SEQ ID NO: 1). In certain embodiments, the anti-TALEN antibodies of the present disclosure specifically bind to a TALEN protein and / or a FokI catalytic domain at a concentration of 1×10 -6 Less than M, 1×10 -7 Less than M, 1×10 -8 Less than M or 1×10 -9 In certain embodiments, the anti-TALEN antibody binds to the TALEN protein and / or FokI catalytic domain with a KD of less than 1×10 -7 In another embodiment, the anti-TALEN antibody binds to the TALEN protein and / or FokI catalytic domain with a KD of less than 1×10 -8In some embodiments, the anti-TALEN antibody binds to the TALEN protein and / or FokI catalytic domain with a KD of less than about 1×10 -7 M, approx. 2 x 10 -7 M, about 3 x 10 -7 M, approx. 4 x 10 -7 M, about 5 x 10 -7 M, about 6 x 10 -7 M, about 7 x 10 -7 M, about 8 x 10 -7 M, about 9 x 10 -7 M, about 1 x 10 -8 M, approx. 2 x 10 -8 M, about 3 x 10 -8 M, approx. 4 x 10 -8 M, about 5 x 10 -8 M, about 6 x 10 -8 M, about 7 x 10 -8 M, about 8 x 10 -8 M, about 9 x 10 -8 M, about 1 x 10 -9 M, approx. 2 x 10 -9 M, about 3 x 10 -9 M, approx. 4 x 10 -9 M, about 5 x 10 -9 M, about 6 x 10 -9 M, about 7 x 10 -9 M, about 8 x 10 -9 M, about 9 x 10 -9 M, about 1 x 10 -10 M, or approximately 5 x 10 -10 M. In certain embodiments, the Kd is off / K on It is calculated as the quotient of K on and K. off is determined using a monovalent antibody, such as a Fab fragment, as measured, for example, by BIAcore® surface plasmon resonance technology. In other embodiments, Kd is off / K on It is calculated as the quotient of K on and K. off is determined, for example, using a bivalent antibody such as a Fab fragment, measured by BIAcore® surface plasmon resonance technology.

[0074] In some embodiments, the anti-TALEN antibody is administered to the TALEN protein and / or FokI catalytic domain at a concentration of 1×10 -4 M -1 s -1 Less than 2×10 -4 M -1 s -1 Less than 3×10 -4 M -1 s -1 Less than 4×10 -4 M -1 s -1 Less than 5×10 -4 M -1 s -1 Less than 7×10 -4 M -1 s -1 Less than 8×10 -4 M -1 s -1 Less than 9×10 -4 M -1 s -1 Less than 1×10 -5 M -1 s -1 Less than 2×10 -5 M -1 s -1 Less than 3×10 -5 M -1 s -1 Less than 4×10 -5 M -1 s -1 Less than 5×10 -5 M -1 s -1 Less than 6×10 -5 M -1 s -1 Less than 7×10 -5 M -1 s -1 Less than 8×10 -5 M -1 s -1 Less than 9×10 -5 M -1 s -1 Less than 1×10 -6 M -1 s -1 Less than 2×10 -6 M -1 s -1 Less than 3×10 -6 M -1 s-1 Less than 4×10 -6 M -1 s -1 Less than 5×10 -6 M -1 s -1 Less than 6×10 -6 M -1 s -1 Less than 7×10 -6 M -1 s -1 Less than 8×10 -6 M -1 s -1 Less than 9×10 -6 M -1 s -1 Less than or equal to 1 × 10 -7 M -1 s -1 Association rate (k on In certain embodiments, k on can be determined using a monovalent antibody, such as a Fab fragment, measured, for example, by BlAcore® surface plasmon resonance technology. on is determined, for example, using bivalent antibodies measured by BlAcore® surface plasmon resonance technology.

[0075] In some embodiments, the anti-TALEN antibody is administered to the TALEN protein and / or FokI catalytic domain at a concentration of 1×10 -2 s -1 Less than 2×10 -2 s -1 Less than 3×10 -2 s -1 Less than 4×10 -2 s -1 Less than 5×10 -2 s -1 Less than 6×10 -2 s -1 Less than 7×10 -2 s -1 Less than 8×10 -2 s -1 Less than 9×10 -2 s -1 Less than 1×10 -3 s -1 Less than 2×10 -3 s-1 Less than 3×10 -3 s -1 Less than 4×10 -3 s -1 Less than 5×10 -3 s -1 Less than 6×10 -3 s -1 Less than 7×10 -3 s -1 Less than 8×10 -3 s -1 Less than 9×10 -3 s -1 Less than 1×10 -4 s -1 Less than 2×10 -4 s -1 Less than 3×10 -4 s -1 Less than 4×10 -4 s -1 Less than 5×10 -4 s -1 Less than 6×10 -4 s -1 Less than 7×10 -4 s -1 Less than 8×10 -4 s -1 Less than 9×10 -4 s -1 Less than 1×10 -5 s -1 Less than or 5×10 -4 s -1 Dissociation constant (k off In certain embodiments, k off is determined using a monovalent antibody, such as a Fab fragment, measured, for example, by BlAcore® surface plasmon resonance technology. off is determined, for example, using bivalent antibodies measured by BlAcore® surface plasmon resonance technology.

[0076] The anti-TALEN antibody provided herein binds to a TALEN protein comprising a variable heavy chain (VH) and / or a FokI catalytic domain, and the amino acid sequence or polynucleotide sequence of the VH is selected from the VH sequences listed in Table 1a. The anti-TALEN antibody specifically binds to a FokI catalytic domain comprising a variable heavy chain (VH), and the amino acid sequence or polynucleotide sequence of the VH is selected from the VH sequences listed in Table 1a. In some embodiments, the VH amino acid sequence is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the VH sequence listed in Table 1a. Kabat CDR definitions are shown in bold, and Chothia CDR definitions are underlined.

[0077] [Table 1]

[0078] Provided herein is an anti-TALEN antibody that specifically binds to Fok1 catalytic domain comprising variable light chain (VL), and the amino acid sequence or polynucleotide sequence of VL is selected from the VL sequence presented in Table 1b. In some embodiments, the VL amino acid sequence is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the VL sequence presented in Table 1b. Kabat CDR definitions are shown in bold, and Chothia CDR definitions are underlined.

[0079] [Table 2]

[0080] Provided herein is an anti-TALEN antibody that specifically binds to the Fok1 catalytic domain, the anti-TALEN antibody comprising a variable heavy chain (VH) and a variable light chain (VL), wherein the amino acid sequence or polynucleotide sequence of the VH is selected from the VH sequences presented in Table 1a, and the amino acid sequence or polynucleotide sequence of the VL is selected from the VL sequences presented in Table 1b.

[0081] In some embodiments, the anti-TALEN antibody that specifically binds to the Fok1 catalytic domain comprises the VH CDR1, CDR2 and CDR3 of the VH sequence presented in Table 1a. In some embodiments, the VH CDR1, CDR2 and CDR3 are selected from the CDR sequences presented in Table 1c.

[0082] [Table 3]

[0083] In some embodiments, the anti-TALEN antibody that specifically binds to the Fok1 catalytic domain comprises the VL CDR1, CDR2 and CDR3 of the VL sequence presented in Table 1b. In some embodiments, the VH CDR1, CDR2 and CDR3 are selected from the CDR sequences presented in Table 1d.

[0084] [Table 4]

[0085] The implementation of the methods disclosed herein, and the preparation and use of the compositions, unless otherwise indicated, utilizes molecular biology, biochemistry, computational chemistry, protein engineering, antibody structure and function, cell culture, recombinant DNA and related fields that are within the skill of the art.These techniques are fully described in the literature.See, for example, Sambrook et al.MOLECULAR CLONING: A LABORATORY MANUAL, Second edition, Cold Spring Harbor Laboratory Press, 1989 and Third edition, 2001 and subsequent editions; Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, 1987 and periodic updates; METHODS IN ENZYMOLOGY series, Academic Press, San Diego; Wolffe, CHROMATIN STRUCTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998 and subsequent editions.

[0086] Genome editing technology TAL effector nucleases TAL effector nuclease (TALEN) typically refers to the restriction enzyme that can be engineered to cut specific sequences of DNA. They generally include a TAL effector DNA binding domain and a DNA cutting domain, i.e., a nuclease that cuts DNA strands. TAL effector (TALE) can be engineered to bind to virtually any desired DNA sequence. Thus, TALEN can be introduced into cells for use in gene editing or genome editing in situ.

[0087] Various non-specific DNA cleavage domains can be used in TALEN constructs, including but not limited to wild-type FokI cleavage domain, part of FokI endonuclease, FokI cleavage domain variants, such as those with mutations designed to improve cleavage specificity and cleavage activity. In some embodiments, the FokI domain functions as a dimer, comprising two constructs with DNA binding domains for the target genome with appropriate orientation and spacing. In some embodiments, the TALEN comprises an endonuclease (e.g., FokI) cleavage domain or cleavage half-domain. The disclosed antibodies can be used for any TALEN-mediated gene editing, including targeted integration, and methods and compositions for nuclease-mediated targeted integration are described in International Publication No. WO2015127439A1, which is incorporated by reference in its entirety.

[0088] Zinc Finger Nucleases Zinc finger nucleases (ZFNs) are protein chimeras that contain a zinc finger-based DNA binding domain and a DNA cleavage (i.e., nuclease) domain (e.g., FokI). ZFNs can introduce double-strand breaks (DSBs; cuts at the same or very close points on both strands of a double-stranded DNA molecule) at specific locations within a DNA molecule, which can then be used to disable, replace, insert, or edit a targeted genomic region.

[0089] Zinc fingers are one of the most common DNA-binding motifs found in eukaryotes. These proteins are classified according to the number and location of cysteine ​​and histidine residues available for zinc coordination. Zinc fingers consist of two antiparallel strands, and an α-helix. The zinc ion is essential for the stability of this domain type, and in the absence of the metal ion, the domain unfolds because it is too small to have a hydrophobic core. One very well-known subset of zinc fingers (C2H2 class) contains a pair of cysteine ​​residues in the beta strand and two histidine residues in the alpha helix that are involved in binding the zinc ion. The other two classes of zinc finger proteins are the C4 and C6 classes. Zinc fingers are important in regulation because they provide a unique structural motif for DNA-binding proteins when interacting with DNA and the zinc ion. The structure of each individual finger is highly conserved, consisting of about 30 amino acid residues organized as a ββα fold and held together by the zinc ion. The α-helix occurs in the C-terminal portion of the finger, while the β-sheet occurs in the N-terminal portion.

[0090] Due to its assumed modularity, the DNA binding domain of ZFN can contain 2-8 zinc finger motifs. In some embodiments, ZFN contains 2, 3, 4, 5, 6, 7, or 8 zinc finger motifs. Each zinc finger motif is typically believed to recognize and bind to a 3 base pair sequence, and thus, proteins containing more zinc fingers target longer sequences and therefore have higher specificity and affinity for the target site. Methods for engineering zinc finger binding domains to bind to a selected sequence are well known in the art. See, e.g., Beerli et al. (2002) Nature Biotechnol. 20:135-141; Pabo et al. (2001) Ann. Rev. Biochem. 70:313-340; Isalan et al. (2001) Nature Biotechnol. 19:656-660; Segal et al. (2001) Curr. Opin. Biotechnol. 12:632-637; Choo et al. (2000) Curr. Opin. Struct. Biol. 10:411-416. Zinc finger engineering methods known in the art include, but are not limited to, rational design and various types of selection. Rational design includes, for example, the use of a database containing triple (or quadruple) nucleotide sequences and individual zinc finger amino acid sequences, where each triple or quadruple nucleotide sequence is associated with one or more amino acid sequences of zinc fingers that bind to a particular triple or quadruple sequence. See, for example, U.S. Patent Nos. 6,453,242 and 6,534,261. Depending on the required specifications of the final product, the zinc fingers to be included can be selected via parallel, serial or dual particle techniques, or via in vitro cell-based techniques.Exemplary selection methods, including phage display and two-hybrid systems, are also known in the art, see U.S. Patent Nos. 5,789,538; 5,925,523; 6,007,988; 6,013,453; 6,410,248; 6,140,466; 6,200,759; and 6,242,568; and International Patent Publication Nos. 98 / 37186; 98 / 53057; 00 / 27878; and 01 / 88197. Enhancement of binding specificity for zinc finger binding domains has been described, for example, in International Publication No. WO 02 / 077227.

[0091] The non-specific nuclease domain of FokI is functionally independent of its native DNA binding domain and can therefore be utilized in the construction of ZFNs. Because the domains must dimerize to achieve double stranded breaks, the nuclease must also be bound to the opposing strand by another ZFN molecule bound to its target sequence, as shown in the figure. The two target sites do not need to be the same, as long as there is a ZFN that targets both sites. To form a dimer, the two ZFN molecules must meet their respective recognition sites that are more than 4-6 base pairs apart, but not so far apart that they cannot dimerize. As shown in the figure, one ZFN molecule binds to its target sequence on one strand, while another ZFN molecule binds to its target sequence on the opposite strand. The nuclease domains dimerize, each cleaving its own strand to create a DSB. FokI can be used as a homodimer or heterodimer. In some embodiments, FokI is a homodimer. In some embodiments, FokI is a heterodimer.

[0092] RNA-guided FokI nuclease RNA-guided FokI nuclease (RFN) is a protein chimera that contains a Cas9 nuclease (Cas9) DNA binding domain and a DNA cleavage domain (e.g., a FokI cleavage domain). RFN specifically targets a given DNA sequence through the use of a guide RNA (gRNA) that generates a 17-20 nucleotide topological complementarity at the 5' end of the target region. RFN introduces a double-strand break (DSB; a cut at the same or very close points on both strands of a double-stranded DNA molecule) at a specific location within the DNA molecule, and then requires dimerization of the FokI DNA cleavage domain to disable, replace, insert, or edit the target genomic region.

[0093] CRISPR CRISPR-associated Cas systems have evolved in bacteria and archaea to guide DNA cleavage complexes to specific nucleotide sequences using short RNAs. The CRISPR / Cas system has been adapted for genome editing in eukaryotic cells. Cas9 releases the DNA and checks the complementarity of the gRNA to the 20 base pair spacer region, thereby specifically targeting the DNA sequence preceding the protospacer adjacent motif (PAM) sequence in the mammalian cell genome. The introduction of DSBs allows for targeted sequence modification through one of two endogenous DNA repair mechanisms: non-homologous end joining (NHEJ) or homology-directed repair (HDR). The CRISPR / Cas system has also been used for gene regulation, including transcriptional repression and activation, without altering the target sequence. Targeted gene regulation based on the CRISPR / Cas system uses an enzymatically inactive Cas9 (dCas9). Additional Cas9 descriptions and gRNA requirements for programmable dCas9 are incorporated by reference in, but not limited to, U.S. Patent Nos. 14 / 536319, 14 / 320498, and 14 / 320467.

[0094] Genome editing system As mentioned above, TALEN, ZFN and RFN can bind and cleave target sites in genome, which allows insertion or deletion of specific DNA sequences, especially when repair template is provided.Selective cleavage is achieved through sequence-specific targeting by DNA binding domain (e.g., TAL effector DNA binding domain) and DNA cleavage by FokI nuclease.After TALEN construct creates double-strand break at target locus, homologous recombination mechanism checks the homology between damaged chromosome and extrachromosomal fragment, regardless of whether the fragment contains original sequence, and copies the sequence of the fragment between the two cut ends of chromosome, resulting in the insertion of the gene of interest into genome.

[0095] In addition to homology-mediated gene editing, the TALEN approach can also be applied to gene editing (knockouts and insertions) mediated by non-homologous end joining.

[0096] In some embodiments, the genome editing system comprises one, two, three, four, five, six, seven, eight or more nucleic acid constructs (or constructs) encoding "half TALENs" that assemble to form a complete TALEN with targeted FokI-mediated nuclease activity. In some embodiments, the genome editing system comprises two or four nucleic acid constructs encoding "half TALENs" with targeted FokI-mediated nuclease activity. In some embodiments, the nucleic acid encodes a dimeric TALEN or a TALEN that comprises two "half TALENs".

[0097] In some embodiments, the genome editing system includes a polynucleotide construct that generates a donor sequence that undergoes genome insertion after nuclease cleavage. In some embodiments, the donor sequence has one or more homologous region(s) that share identity to the genome sequence with which recombination is desired. In some embodiments, the donor sequence has one or more homologous region(s) that have at least 50% sequence identity to the genome sequence with which recombination is desired. In some embodiments, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or 99.9% sequence identity is present across the homologous regions. Depending on the length of the donor polynucleotide, there may be any value of sequence identity between 1% and 100%.

[0098] In some embodiments, as part of gene therapy, DNA can be introduced into selected target cells in such a manner that the donor DNA is expressed and produces the therapeutic product encoded thereby. Additionally or alternatively, the donor DNA can in some way mediate the expression of the DNA encoding the therapeutic product, or can encode a product such as a peptide or RNA that in some way mediates the expression of the therapeutic product directly or indirectly. In some embodiments, the donor DNA encodes a therapeutic product for the treatment or prevention of a disease or disorder caused by a gene defect or deficiency. In some embodiments, the donor DNA encodes a therapeutic product for the treatment or prevention of cancer or any other disease or disorder caused by a gene defect or deficiency. In some embodiments, the donor DNA encodes a chimeric antigen receptor (CAR).

[0099] The techniques and protocols for genome editing are described in the art.See, for example, US Patent No. 2005 / 0215502; US Patent No. 2007 / 0134796; International Publication No. 2005 / 084190; International Publication No. 2014204578; Urnov et al., Nature Reviews Genetics 11,636-646(2010); Rahman et al., Human Gene Therapy 22(8):925-933(2011); Tsai et al., Nature Biotechnology(2014)32: 569-576; and Collins et al., Proceedings Biological Sciences / The Royal Society,282(1821):pii 20143003(2015).For example, genome editing can be carried out in vivo or ex vivo (e.g., in vitro). In some embodiments, viral and non-viral based gene transfer methods can be used to introduce nucleic acids encoding TALENs, ZFNs, or RFNs into mammalian cells or target tissues. Such methods can be used to administer nucleic acids encoding TALENs, ZFNs, or RFNs to cells in vitro. In some embodiments, non-viral vector delivery systems include DNA plasmids, naked nucleic acids, and delivery vectors such as poloxamers or liposomes. HIn some embodiments, the nucleic acid encoding the TALEN, ZFN, or RFN is transfected via electroporation. In some embodiments, the non-viral delivery system includes direct introduction of mRNA encoding the TALEN, ZFN, or RFN, such as by microinjection. Viral vector delivery systems include DNA and RNA viruses that have either episomal or integrated genomes after delivery to cells. Examples of viral vector delivery systems include, but are not limited to, integrase-deficient lentiviral vectors, adenoviral vectors, and vectors based on adeno-associated viruses. In some embodiments, the components of the genome editing system are mixed before being administered to a subject. In some embodiments, the components of the genome editing system are administered separately. Separate administration of genome editing components can be essentially simultaneous, sequential, or separated by a determined period of time.

[0100] Described herein are highly sensitive and reliable methods for detecting and / or measuring FokI in a sample. As shown herein, these methods are capable of detecting FokI at physiological levels.

[0101] Detection part As used herein, a detection moiety includes any portion of a structure capable of being detected by any method known in the art. A detection moiety refers to any element, molecule, functional group, compound, fragment or moiety that is detectable. Detection moieties include radionuclides (e.g., 3 H, 14 C. 18 F, 19 F, 32 P, 35 S, 135 I, 125 I, 123 I, 64 Cu, 187 Re, 111 In, 90 Y, 99m Tc, 177 Lu, 89Zr, etc.), fluorescent dyes (e.g., fluorescein dyes, acridine dyes, SYBR dyes, rhodamine dyes, oxazine dyes, etc.), chemiluminescent agents (e.g., acridinam esters, stabilized dioxatanes, etc.), electrochemiluminescent agents (e.g., sulfotags, etc.), bioluminescent agents (e.g., luciferin, etc.), spectrally resolvable inorganic fluorescent semiconductor nanocrystals (i.e., quantum dots), metal nanoparticles (e.g., gold, silver, copper, platinum, etc.), nanoclusters, paramagnetic metal ions, enzymes (e.g., horseradish peroxidase, alkaline phosphatase, etc.), colorimetric labels (e.g., dyes, colloidal gold, etc.), biotin, digoxigenin, haptens, and proteins for which antisera or monoclonal antibodies are available.

[0102] In some embodiments, anti-FokI antibody is bound to detection moiety.Anti-FokI antibody can be covalently or non-covalently bound to detection moiety.In some embodiments, detection moiety is selected from sulfo-tag, horseradish peroxidase, alkaline phosphatase, FITC, digoxigenin, acridan, RPE, luciferin, fluorophore, chromophore, radioisotope, or biotin.

[0103] In some embodiments, the detection moiety is an electrochemiluminescent (ECL) label. In general, ECL-based assays involve the use of an electrochemiluminescent compound as a label (referred to herein as an ECL label). Any compound capable of electrochemiluminescence can be used as an ECL label. Examples of ECL labels include, but are not limited to, organometallic compounds, such as tris-bipyridyl-ruthenium (RuBpy) moieties, where the metal is derived from group VII and group VIII metals, including, for example, Re, Ru, Ir, and Os. In some embodiments, the ECL label is a sulfo-tag label. Species that react with the ECL label in the ECL process are referred to herein as ECL coreactants. Commonly used coreactants for ECL include tertiary amines (e.g., tripropylamine (TPA)), oxalates, and persulfates.

[0104] In some embodiments, anti-TALEN antibody is bound to detection moiety. Detection moiety can be bound to anti-TALEN antibody through covalent or non-covalent bond. Covalent binding of detection moiety to anti-TALEN antibody can be direct or through linker. In some embodiments, detection moiety is selected from ECL tag (e.g., sulfo-tag), horseradish peroxidase, alkaline phosphatase, FITC, digoxigenin, acridan, RPE, luciferin, fluorophore, chromophore, radioisotope, or biotin.

[0105] The anti-TALEN antibodies described herein can be used in any assay known in the art to measure the presence or intensity of the detection moiety in an immunoassay. In some embodiments, the detection of the presence or absence of FokI containing molecules (e.g., TALEN proteins) includes measuring electrochemiluminescence, luminescence, fluorescence, or absorbance by any means known in the art. The detection step can involve a quantitative measurement that can be used to determine the amount of FokI polypeptide in a sample. The measurement(s) for determining the presence or intensity of FokI can be performed by manual methods or can be performed using an apparatus such as an analyzer. For example, in some embodiments, the detection moiety can produce a color output. The method can include the visual appearance of a colored product and / or can use an apparatus such as an analyzer to detect or quantify the color product. In some embodiments, the detection step includes measuring electrochemiluminescence, which can be performed using commercially available equipment.

[0106] In some embodiments, the detection moiety is a fluorescent label, a photochromic compound, a proteinaceous fluorescent label, a magnetic label, a radiolabel, or a hapten. In some embodiments, the detectable label is an Atto dye, an Alexa Fluor dye, a quantum dot, a hydroxycoumarin, an aminocoumarin, a methoxycoumarin, Cascade Blue, Pacific Blue, Pacific Orange, Lucifer Yellow, NBD, R-Phycoerythrin (PE), a PE-Cy5 conjugate, a PE-Cy7 conjugate, a Red 613, PerCP, TruRed, FluorX, Fluorescein, BODIPY-FL, Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy7, TRITC, X-Rhodamine, Lissamine Rhocamine B, Texas Red, Allophycocyanin (APC), APC-Cy7 conjugate, Indo-1, Fluo-3, Fluo-4, DCFH, DHR, SNARF, GFP (Y66H mutant), GFP (Y66F mutation), EBFP, EBFP2, Azurite, GFPuv, T-Sapphire, Cerulean, mCFP, mTurquoise2, ECFP, CyPet, GFP (Y66W mutation), mKeima-Red, TagCFP, AmCyan1, mTFP1, GFP (S65A mutation), Greenish cyan, wild-type GFP, GFP (S65C mutation), TurboGFP, TagGFP, GFP (S6 The fluorescent label is selected from the group consisting of: mKate (TagFP635), Emerald, GFP (S65T mutation), EGFP, Thistle Green, ZsGreen1, TagYFP, EYFP, Topaz, Venus, mCitrine, YPet, TurboYFP, ZsYellow1, Kusabira Orange, mOrange, Allophycocyanin (APC), mKO, TurboRFP, tdTomato, TagRFP, DsRed monomer, DsRed2, mStrawberry, TurboFP602, AsRed2, mRFP1, J-Red, R-Phycoerythrin (RPE), B-Phycoerythrin (BPE), mCherry, HcRed1, Katusha, P3, Peridinin Chlorophyll (PerCP), mKate (TagFP635), TurboFP635, mPlum, and mRaspberry.

[0107] Type 2 restriction enzyme FokI FokI is a bacterial type IIS restriction enzyme found naturally in Flavobacterium okeanokoites. Native FokI consists of an N-terminal DNA binding domain and a C-terminal nonspecific DNA cleavage domain. (UniProt accession no. P14870) The full-length wild-type FokI amino acid sequence is (SEQ ID NO:2).

[0108] The FokI DNA cleavage domain can function independently of the DNA binding domain. In some embodiments, the FokI polypeptide consists of, consists essentially of, or comprises a FokI nuclease domain. In some embodiments, the FokI catalytic domain polypeptide is wild-type amino acids 439-583 of SEQ ID NO:2. In some embodiments, the anti-TALEN antibodies described herein bind to a molecule comprising SEQ ID NO:1. MKVMEFFMKVYGYRGKHLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEENQTRNKHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNCNGAVLSVEELLIGGEMIKAGTLTLEEVRRKFNNGEINF (SEQ ID NO: 1)

[0109] In some embodiments, the FokI protein is modified. In some embodiments, the modified FokI protein comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the wild-type FokI catalytic domain (SEQ ID NO:1). In some embodiments, the FokI protein comprises a biologically active fragment of FokI. In some embodiments, the biologically active fragment comprises the catalytic domain of FokI. In some embodiments, the FokI protein comprises a DNA cleavage domain of FokI. In some embodiments, the FokI protein comprises an amino acid sequence that differs from SEQ ID NO:1 by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, or more amino acids.

[0110] Sample Type Sample types of the present disclosure include any material that has, is suspected to have, is likely to have, or is confirmed to have a molecule that includes a TALEN protein or a FokI catalytic domain. In some embodiments, the sample is an in vitro sample. In some embodiments, the sample is an in vivo sample. In some embodiments, the sample is of biological origin (e.g., a biological sample). A biological sample includes any material that was once part of a living organism. In some embodiments, the biological sample is from a mammal. Mammals include, but are not limited to, humans, dogs, cats, cows, pigs, sheep, non-human primates, and llamas. Humans can be of any age. Biological samples can be in any form, including, but are not limited to, cells, tissues, whole blood, plasma, serum, urine, feces, saliva, spinal blood, sperm, aqueous humor or vitreous humor, chorionic villus samples, and combinations thereof. In some embodiments, the sample is a tissue sample, a blood sample, a formalin-fixed sample, an ex vivo grown tissue, or cell culture media. In some embodiments, a sample, for example a serum sample, is analyzed for the presence (or absence) or level of a TALEN protein or a FokI protein.

[0111] kit Also provided herein are kits for use in detecting and / or measuring FokI in samples (e.g., biological samples) as described herein. Such kits typically include one or more substances, reagents and / or materials for use in the methods provided herein. The kits may include instructions for carrying out such methods. Kits for detecting and / or measuring FokI may include various reagents necessary to analyze 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1000 or more samples. In some embodiments, the kits may allow for simultaneous or near-simultaneous analysis of multiple samples, such as microplate-type assay kits. In some embodiments, the kits may be disposable, such that the reagents and materials are intended for a single use and / or are intended to be discarded after the performance of the assay.

[0112] In some embodiments, the kit for use in detecting and / or measuring FokI in a sample may include an anti-TALEN antibody described herein, optionally conjugated to a detection moiety, or may include a substance that allows the use of the kit to perform such conjugation. The substrate of the FokI detection kit described herein may take any suitable form that allows binding of the anti-FokI antibody described herein to a FokI-containing complex. In some embodiments, the substance is contained in or is part of a microplate. Any suitable detection moiety known in the art may be used. For example, detection moieties include, but are not limited to, ECL tags (e.g., sulfo-tags), horseradish peroxidase, alkaline phosphatase, FITC, digoxigenin, acridan, RPE, luciferin, fluorophores, chromophores, radioisotopes, or biotin. Furthermore, any suitable detection method may be used in conjunction with the FokI detection kit described herein. The kit may or may not include reagents, substances, and / or equipment for detecting or measuring signals. In some embodiments, the use of the kit may include detection of a signal, including measurement of electrochemiluminescence, luminescence, fluorescence, or absorbance. Detection of a signal associated with the anti-FokI detection assay may be by any means known in the art. The associated kit may or may not include instructions for a particular detection method. In some embodiments, the kit may refer the user to a standard method of detection. In some embodiments, the kit may refer the user to follow instructions associated with other devices for detection.

[0113] Typical Use In some embodiments, the disclosed methods and kits can be used for evaluation and / or monitoring of cell or gene therapy, such as CAR T therapy. In some embodiments, the cell or gene therapy is ZFN-based gene therapy. In some embodiments, the cell or gene therapy is RFN-based gene therapy. In some embodiments, the cell therapy is TALEN-based gene therapy. In some embodiments, the cell or gene therapy comprises administration of a DNA construct. In some embodiments, the cell or gene therapy comprises mRNA replacement therapy. In some embodiments, the cell or gene therapy comprises cell replacement therapy, such as chimeric antigen receptor (CAR)-based therapy, which may include allogeneic or autologous cell replacement. The cell replacement therapy may comprise administering cells transduced or transfected with a nucleic acid construct encoding FokI protein or a biologically active fragment thereof.

[0114] In some embodiments, samples for evaluating and / or monitoring cell or gene therapy can be obtained before the start of therapy. In some embodiments, samples are obtained after the first cell or gene therapy treatment or administration. In some embodiments, samples are obtained after the completion of gene therapy. In some embodiments, samples are obtained at specific time points, intervals, or any other time measurement before, during, or after cell or gene therapy is performed. In some embodiments, FokI detection is used to evaluate the potential of cell or gene therapy.

[0115] Treatment method In some embodiments, the anti-TALEN antibodies of the present disclosure can be used for evaluation and / or monitoring of gene therapy or cell therapy replacement therapy, such as CAR therapy. In some embodiments, gene therapy involves administering to a patient a cell population engineered with a TALEN protein to express a chimeric antigen receptor (CAR). CARs containing immune cells can be used to treat malignancies involving abnormal expression of biomarkers, including cancer. In some embodiments, CARs containing immune cells of the present disclosure can be used to treat non-Hodgkin's lymphoma, such as diffuse large B-cell lymphoma (DLBCL), leukemia (e.g., CLL or ALL), multiple myeloma (MM), small cell lung cancer, melanoma, low-grade glioma, glioblastoma, medullary thyroid carcinoma, carcinoid, dispersed neuroendocrine tumors in the pancreas, bladder and prostate, testicular cancer, and lung adenocarcinoma with neuroendocrine features.

[0116] As used herein, the term "cancer" includes, but is not limited to, solid tumors and blood-borne tumors. The term "cancer" refers to diseases of the skin tissue, organs, blood, and blood vessels, including, but not limited to, cancer of the bladder, bone or blood, brain, breast, cervix, breast, colon, endometrium, esophagus, eye, head, kidney, liver, lymph nodes, lung, mouth, neck, ovary, pancreas, prostate, rectum, stomach, testicles, throat, and uterus. Specific cancers include: advanced malignant tumors, amyloidosis, neuroblastoma, meningioma, hemangiopericytoma, multiple brain metastases, glioblastoma multiforme, glioblastoma, brain stem glioma, malignant brain tumors with poor prognosis, malignant glioma, recurrent malignant glioma, malignant astrocytoma, anaplastic oligodendroglioma, neuroendocrine tumor, rectal adenocarcinoma, Dukes C and D colon cancer, unresectable colorectal cancer, metastatic hepatocellular carcinoma, Kaposi's sarcoma, karyotype acute myeloblastic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma (NHL), cutaneous T-cell lymphoma, cutaneous B-cell lymphoma, diffuse large B-cell lymphoma, low-grade follicular lymphoma, malignant melanoma, malignant mesothelioma, malignant The cancer includes, but is not limited to, carcinomatous pleural effusion melanoma syndrome, peritoneal cancer, serous papillary carcinoma, gynecological sarcoma, soft tissue sarcoma, scleroderma, cutaneous vasculitis, Langerhans cell histiocytosis, leiomyosarcoma, fibrodysplasia ossificans progressiva, hormone refractory prostate cancer, resected high-risk soft tissue sarcoma, unresectable hepatocellular carcinoma, Waldenstrom's hypergammaglobulinemia, smoldering myeloma, low-grade myeloma, fallopian tube cancer, androgen-independent prostate cancer, androgen-dependent stage IV non-metastatic prostate cancer, hormone-insensitive prostate cancer, chemotherapy-insensitive prostate cancer, papillary thyroid cancer, follicular thyroid cancer, medullary thyroid cancer, and leiomyoma. In certain embodiments, the cancer is metastatic. In another embodiment, the cancer is refractory or resistant to chemotherapy or radiation. In a further embodiment, the cancer is reduced to a level determined to be less than desirable and retreatment is determined to be appropriate. EXAMPLES

[0117] Example 1: Generation of anti-TALEN antibodies To generate hybridoma cells, wild-type Balb / c mice were immunized with FokI catalytic domain protein containing C-terminal 6xHis tag and GSGS linker. Cells from Balb / c mice on day 12 of immunization were fused using repetitive immunization multiple sites (RIMMS) to obtain hybridoma fusion number 2296. The resulting antibodies were screened for ELISA positivity on FokI catalytic domain and counterscreened using His-tag antigen. Samples were screened on full-length TALEN protein containing C-terminal 6xHis tag and GSGS linker. Antibodies were analyzed by Western blot and evaluated using Biacore® for binding confirmation and kinetics.

[0118] Antibodies from fusion #2296 were screened on FokI and full-length TALEN protein, yielding over 30 ELISA positives. These antibodies were negative for His-tag antigen. Biacore® analysis of fusion #2296 antibodies yielded kD values ​​ranging from 5 nM to 100 nM. Biacore® kinetics of fusion #2296 RIMMS day 12 are shown in Table 2 below.

[0119] [Table 5]

[0120] Hybridoma fusion #2299 cells were obtained from long-term immunization on day 94. Balb / c mouse #2299 with higher antibody titer was selected for fusion. Antibodies obtained from fusion #2299 were screened on FokI and full-length TALEN protein to obtain more than 68 ELISA positives. These antibodies were negative for His-tag antigen. Biacore® analysis of fusion #2299 antibodies yielded kD values ​​ranging from half nM to 100 nM. Five of the top 12 ELISA binders were positive in Western blot analysis with supernatants (Figure 1). Biacore® kinetics of exemplary antibodies derived from fusion #2299 are shown in Table 3 below. [Table 6]

[0121] The purified antibodies shown in Table 4 below were selected for further analysis and assay development. [Table 7]

[0122] Equivalents and Scope Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the disclosure described herein. The scope of the disclosure is not intended to be limited to the above description, but rather is as set forth in the following claims.

Claims

1. An antibody specific for the FokI nuclease catalytic domain comprising the amino acid sequence of SEQ ID NO:1, comprising a variable heavy chain (VH) amino acid sequence that is at least 90% identical to SEQ ID NO:3 and a variable light chain (VL) amino acid sequence that is at least 90% identical to SEQ ID NO:7; (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12 or 14; (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 15 or 18; (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21; (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:22; (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 23; and (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:

26. Contains or (g) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 13 or 14; (h) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 16 or 19; (i) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21; (j) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22; (k) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 25; and (l) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 26 Contains or (m) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12 or 14; (n) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 15 or 18; (o) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21; (p) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22; (q) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 24; and (r) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 28 Contains or (s) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12 or 14; (t) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 17 or 20; (u) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21; (v) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:22; (w) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 24; and (x) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 27 Contains or (y) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12 or 14; (z) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 15 or 18; (aa) a VH CDR3 comprising the amino acid sequence of SEQ ID NO:21; (bb) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22; (cc) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 24; and (dd) The antibody comprising a VL CDR3 comprising the amino acid sequence of SEQ ID NO:

27.

2. The antibody of claim 1, comprising a VH amino acid sequence that is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:3, or a VL amino acid sequence that is at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:

7.

3. The antibody of claim 1 further comprising a detectable label.

4. The antibody of claim 3 , wherein the detectable label is selected from the group consisting of a fluorescent label, a photochromic compound, a proteinaceous fluorescent label, a magnetic label, a radiolabel, and a hapten.

5. The antibody of claim 4, wherein the fluorescent label is R-phycoerythrin (PE) or allophycocyanin (APC).

6. A composition comprising the antibody of claim 1 and a pharma- ceutically acceptable carrier or vehicle.

7. A method for producing the antibody of claim 1, comprising incubating under suitable conditions a cell containing one or more vectors comprising a polynucleotide encoding the heavy chain of the antibody and a polynucleotide encoding the light chain of the antibody.

8. A method for determining the presence of a FokI nuclease catalytic domain comprising the amino acid sequence of SEQ ID NO:1 in a sample, the method comprising contacting the sample with an antibody described in claim 1 conjugated to a detectable label, and determining the presence of the FokI nuclease catalytic domain in the sample.

9. The method of claim 8, wherein the detectable label is selected from the group consisting of a fluorescent label, a photochromic compound, a proteinaceous fluorescent label, a magnetic label, a radioactive label, and a hapten.

10. 9. The method of claim 8, wherein the sample is an immune cell sample, a tissue sample, a blood sample, a formalin-fixed sample, an ex vivo grown tissue or a cell culture medium.

11. 10. The method of claim 9, wherein the sample is an immune cell sample, a tissue sample, a blood sample, a formalin-fixed sample, an ex vivo grown tissue or a cell culture medium.

12. An antibody specific to the FokI nuclease catalytic domain comprising the amino acid sequence of SEQ ID NO:1, comprising: (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12 or 14; (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 15 or 18; (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21; (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:22; (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 23; and (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 26; and The antibody comprises a VH comprising the amino acid sequence of SEQ ID NO:3; and a VL comprising the amino acid sequence of SEQ ID NO:

7.

13. An antibody specific to the FokI nuclease catalytic domain comprising the amino acid sequence of SEQ ID NO:1, comprising: (g) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 13 or 14; (h) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 16 or 19; (i) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21; (j) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22; (k) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 25; and (l) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 26; and The antibody comprises a VH having the amino acid sequence of SEQ ID NO:4; and a VL having the amino acid sequence of SEQ ID NO:

9.

14. An antibody specific to the FokI nuclease catalytic domain comprising the amino acid sequence of SEQ ID NO:1, comprising: (m) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12 or 14; (n) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 15 or 18; (o) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21; (p) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22; (q) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 24; and (r) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 28; and The antibody comprises a VH comprising the amino acid sequence of SEQ ID NO:5; and a VL comprising the amino acid sequence of SEQ ID NO:

10.

15. An antibody specific to the FokI nuclease catalytic domain comprising the amino acid sequence of SEQ ID NO:1, comprising: (s) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12 or 14; (t) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 17 or 20; (u) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21; (v) a VL CDR1 comprising the amino acid sequence of SEQ ID NO:22; (w) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 24; and (x) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 27; and The antibody comprises a VH comprising the amino acid sequence of SEQ ID NO:6; and a VL comprising the amino acid sequence of SEQ ID NO:

11.

16. An antibody specific to the FokI nuclease catalytic domain comprising the amino acid sequence of SEQ ID NO:1, comprising: (y) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12 or 14; (z) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 15 or 18; (aa) a VH CDR3 comprising the amino acid sequence of SEQ ID NO:21; (bb) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22; (cc) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 24; and (dd) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 27; and The antibody comprises a VH comprising the amino acid sequence of SEQ ID NO:3; and a VL comprising the amino acid sequence of SEQ ID NO:

8.

17. A method for determining the presence of a FokI nuclease catalytic domain comprising the amino acid sequence of SEQ ID NO:1 in a sample, the method comprising contacting the sample with an antibody described in claim 1 and determining the presence of the FokI nuclease catalytic domain in the sample.

18. 18. The method of claim 17, wherein the sample is an immune cell sample, a tissue sample, a blood sample, a formalin-fixed sample, an ex vivo grown tissue or a cell culture medium.

19. A polynucleotide encoding the antibody of claim 1 or 2.

20. A vector comprising the polynucleotide of claim 19.

21. A cell comprising the polynucleotide of claim 19.

22. A cell comprising the vector of claim 20.

23. 22. A method for producing an antibody specific to the FokI nuclease catalytic domain, comprising incubating the cell of claim 21 under suitable conditions.

24. 23. A method for producing an antibody specific to the FokI nuclease catalytic domain, comprising incubating the cell of claim 22 under suitable conditions.

Citation Information

Patent Citations

  • Methods and compositions for nuclease-mediated targeted integration

    JP2017506898A